Click here to read the original notifications for Amiodarone Hydrochloride Injection 150 mg, Flecainide Tablets 50 mg and Clizapril Tablets 2.5 mg & 5 mg

All of these products will have DUAL listings in the Pharmaceutical Schedule & where applicable HML from 1 September 2019 until 31 January 2020.

We ask that you continue to order the incumbent brand(s) to ensure supplies move through the supply chain with no risk to either pharmacy or wholesaler.

ProPharma /PWR will implement automatic replacement where applicable.

As of the date of this notification ProPharma / PWR cannot accept any of the products listed to be delisted for credit under any circumstances.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 February 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesale and pharmacy, do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close